Kendra Hightower is a dedicated drug discovery leader and scientist with over twenty years of experience in the pharmaceutical industry. They have a strong foundation in biological and chemical sciences, contributing significantly to early drug discovery efforts, drug development programs, and marketed drug support, including the HIV integrase inhibitor Tivicay and the BRaf inhibitor Tafinlar. Currently serving as Senior Vice President of Research & Development at Xilis, Kendra has previously held leadership roles at companies like Merck, GlaxoSmithKline, and Ribometrix, where they established R&D strategies and managed diverse teams of scientists. Kendra's expertise spans a wide range of therapeutic areas, and they are committed to mentoring others and developing scientific strategies to drive innovation in drug discovery.
This person is not in any teams